<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Meister J</submitter><funding>National Institute of Diabetes and Digestive and Kidney Diseases</funding><funding>National Institutes of Health</funding><funding>Lundbeck Foundation</funding><funding>Novo Nordisk Fonden</funding><pagination>101415</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8728399</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>55</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>The goal of this study was to determine the glucometabolic effects of acute activation of G&lt;sub>s&lt;/sub> signaling in skeletal muscle (SKM) in vivo and its contribution to whole-body glucose homeostasis.&lt;h4>Methods&lt;/h4>To address this question, we studied mice that express a G&lt;sub>s&lt;/sub>-coupled designer G protein-coupled receptor (Gs-DREADD or GsD) selectively in skeletal muscle. We also identified two G&lt;sub>s&lt;/sub>-coupled GPCRs that are endogenously expressed by SKM at relatively high levels (β&lt;sub>2&lt;/sub>-adrenergic receptor and CRF&lt;sub>2&lt;/sub> receptor) and studied the acute metabolic effects of activating these receptors in vivo by highly selective agonists (clenbuterol and urocortin 2 (UCN2), respectively).&lt;h4>Results&lt;/h4>Acute stimulation of GsD signaling in SKM i</pubmed_abstract><journal>Molecular metabolism</journal><pubmed_title>In vivo metabolic effects after acute activation of skeletal muscle G&lt;sub>s&lt;/sub> signaling.</pubmed_title><pmcid>PMC8728399</pmcid><funding_grant_id>NNF19OC0056839</funding_grant_id><funding_grant_id>R313-2019-643</funding_grant_id><pubmed_authors>Meister J</pubmed_authors><pubmed_authors>Lee R</pubmed_authors><pubmed_authors>Wess J</pubmed_authors><pubmed_authors>Jensen TE</pubmed_authors><pubmed_authors>Liu L</pubmed_authors><pubmed_authors>Bone DBJ</pubmed_authors><pubmed_authors>Chen M</pubmed_authors><pubmed_authors>Barella LF</pubmed_authors><pubmed_authors>Kleinert M</pubmed_authors><pubmed_authors>Knudsen JR</pubmed_authors><pubmed_authors>Gavrilova O</pubmed_authors><pubmed_authors>Weinstein LS</pubmed_authors></additional><is_claimable>false</is_claimable><name>In vivo metabolic effects after acute activation of skeletal muscle G&lt;sub>s&lt;/sub> signaling.</name><description>&lt;h4>Objective&lt;/h4>The goal of this study was to determine the glucometabolic effects of acute activation of G&lt;sub>s&lt;/sub> signaling in skeletal muscle (SKM) in vivo and its contribution to whole-body glucose homeostasis.&lt;h4>Methods&lt;/h4>To address this question, we studied mice that express a G&lt;sub>s&lt;/sub>-coupled designer G protein-coupled receptor (Gs-DREADD or GsD) selectively in skeletal muscle. We also identified two G&lt;sub>s&lt;/sub>-coupled GPCRs that are endogenously expressed by SKM at relatively high levels (β&lt;sub>2&lt;/sub>-adrenergic receptor and CRF&lt;sub>2&lt;/sub> receptor) and studied the acute metabolic effects of activating these receptors in vivo by highly selective agonists (clenbuterol and urocortin 2 (UCN2), respectively).&lt;h4>Results&lt;/h4>Acute stimulation of GsD signaling in SKM i</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2026-05-28T05:19:33.402Z</modification><creation>2022-02-11T15:08:16.856Z</creation></dates><accession>S-EPMC8728399</accession><cross_references><pubmed>34883278</pubmed><doi>10.1016/j.molmet.2021.101415</doi></cross_references></HashMap>